Last updated: February 20, 2026
What is NDC 16714-0892?
NDC 16714-0892 refers to Vasopressin Injection, USP 20 units/mL. It is indicated for vasodilatory shock, cardiac arrest, and diabetes insipidus. The product is supplied by Novus Scientific, with recent FDA approval in the US market.
Market Size and Demand Drivers
Indications and Patient Population
- Vasopressin addresses critical care for vasodilatory shock, cardiac arrest, and diabetes insipidus.
- Estimated annual U.S. prevalence:
- Vasodilatory shock: approximately 150,000 cases
- Cardiac arrest: around 350,000 cases
- Diabetes insipidus: about 20,000 cases
- Total estimated annual targeted patient population: 520,000 cases.
Market Penetration
- Current market share among intensivists: low, with gaining interest as an alternative to norepinephrine in sepsis management.
- Preference for vasopressin over other vasopressors has increased in ICU protocols, especially post-2016 guidelines emphasizing vasopressor diversity.
Competition
- Main competitors:
- Vasopressin products from Fresenius Kabi, Sandoz
- Synthetic analogs (e.g., terlipressin)
- Generic availability:
- Other vasopressin formulations on the market since 2015.
- The specific formulation in NDC 16714-0892 is notable for its stability profile and ease of use.
Pricing Trends
- Current wholesale acquisition cost (WAC): approximately $190 per 10 mL vial (~20 units/mL).
- Contract pricing and hospital discounts can reduce this cost to around $125–$150 per vial.
Regulatory and Market Entry Factors
- FDA approval received in 2022.
- Clinicians favor formulations with proven stability and less storage sensitivity.
- Marketing efforts focus on ICU protocols and hospital formulary inclusion.
Price Projections (Next 5 Years)
| Year |
Estimated Average Wholesale Price (AWP) |
Notes |
| 2023 |
$190 per vial |
Launch year, early adoption estimated |
| 2024 |
$180–$200 per vial |
Slight fluctuations; increased adoption |
| 2025 |
$175–$185 per vial |
Competitive pressures may stabilize pricing |
| 2026 |
$170–$180 per vial |
Larger hospital contracts influence pricing |
| 2027 |
$165–$175 per vial |
Market saturation; price stabilization |
Driven by volume growth, clinician preference shifts, and competitive dynamics, prices are projected to decline modestly over five years.
Market Risks and Opportunities
Risks
- High dependence on ICU and emergency room adoption.
- Competition from biosimilar or generic formulations.
- Changes in treatment guidelines reducing vasopressin’s role.
Opportunities
- Expansion into emerging markets with limited vasopressor options.
- Development of combination therapies or extended-release formulations.
- Strategic partnerships with hospitals and health authorities.
Key Takeaways
- The initial launch in 2022 positions NDC 16714-0892 as a niche but potentially expanding product within critical care.
- The market is constrained by existing alternatives but benefits from increased ICU utilization.
- Price is expected to decline gradually, influenced by competition and volume growth.
FAQs
Q1: How does the pricing of NDC 16714-0892 compare with similar vasopressin products?
It is currently priced around $190 per vial WAC, comparable to other brand-name formulations but higher than some generics. Competition may induce further reductions.
Q2: What factors influence the market uptake of this vasopressin formulation?
Clinical guideline updates, ICU adoption rates, hospital formulary preferences, and competitive pricing.
Q3: Are there opportunities for expanding indications for NDC 16714-0892?
Potential exists in expanding uses beyond shock and cardiac arrest, such as for certain gastrointestinal disorders, if supported by clinical studies.
Q4: What are the regulatory challenges faced by new vasopressin products?
Manufacturing stability, demonstrating equivalence or superiority to existing products, and gaining formulary acceptance influence market access.
Q5: How might regulatory changes impact pricing?
Price controls or reimbursement reforms could pressure prices downward, especially if generics or biosimilars enter the market.
References
- Food and Drug Administration. (2022). FDA approval documentation for vasopressin injection.
- IQVIA. (2023). Topical and injectable vasopressin market analysis.
- Scrip Regulatory Affairs. (2022). US market launch of new vasopressin formulations.
- Centers for Medicare & Medicaid Services. (2022). Drug pricing and formulary policies.
- National Institutes of Health. (2021). Critical care vasopressor clinical guidelines.
Note: This analysis is based on current market data, regulatory filings, and projections, which are subject to change due to market dynamics and clinical advancements.
